(92 days)
No
The description focuses on the mechanical and RF ablation components of the device and does not mention any AI or ML capabilities.
Yes
The device is described as an "Intracept Intraosseous Nerve Ablation System" with the intended use of ablating basivertebral nerves for the relief of chronic low back pain, which directly indicates a therapeutic purpose.
No
The device is an ablation system used for treating chronic low back pain by ablating basivertebral nerves, not for diagnosing a condition.
No
The device description explicitly lists physical components (access instruments, RF probe) and mentions their use with a radiofrequency generator, indicating it is a hardware-based medical device, not software-only.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens (like blood, urine, or tissue) taken from the human body to provide information about a person's health. This testing is done outside of the body (in vitro).
- Intracept System Function: The Intracept Intraosseous Nerve Ablation System is a surgical device used within the body (in vivo) to directly ablate nerves. It does not analyze samples taken from the patient.
- Intended Use: The intended use clearly describes a procedure performed on the patient's spine for pain relief, not a diagnostic test on a biological sample.
- Device Description: The components described (access instruments, RF probe, generator) are all designed for surgical intervention, not for laboratory analysis of specimens.
Therefore, based on the provided information, the Intracept Intraosseous Nerve Ablation System is a therapeutic device, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Intracept Intraosseous Nerve Ablation System is intended to be used in conjunction with radiofrequency (RF) generators for the ablation of basivertebral nerves of the L3 through S1 vertebrae for the relief of chronic low back pain of at least six months duration that has not responded to at least six months of conservative care, and is also accompanied by features consistent with Type 1 or Type 2 Modic changes on an MRI such as inflammation, edema, vertebral endplate changes, disruption and fissuring of the endplate, vascularized fibrous tissues within the adjacent marrow, hypointensive signals (Type 1 Modic changes to the vertebral body marrow including replacement of normal bone marrow by fat, and hyperintensive signals (Type 2 Modic change).
Product codes
GXI
Device Description
The Intracept Intraosseous Nerve Ablation System) is comprised of sterile, singleuse components:
- The Intracept Access Instruments include introducers, cannulas and stylets that provide access ● to the intended site of radiofrequency (RF) ablation.
- The Intracept RF Probe conducts RF energy to the target location.
To obtain the energy needed for tissue ablation, the Intracept RF Probe is used with the Relievant Radiofrequency Generator (RFG).
The Intracept System uses RF ablation of the basivertebral nerve for relief of chronic low back pain and involves a two-step process. First, utilizing the Access Instruments, based on a minimally invasive, transpedicular or extrapedicular approach, a cannula and stylets are placed into the vertebral body to create a path or channel to the terminus of the basivertebral foramen. The RF Probe is then placed into this channel at the terminus of the basivertebral foramen and controlled RF energy is delivered to ablate the basivertebral nerve (BVN). This nerve has been identified as a proprioceptive sensory nerve with enervation of the vertebral endplates.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
MRI
Anatomical Site
basivertebral nerves of the L3 through S1 vertebrae
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Non-Clinical Performance Testing: Risk analysis of an additional set of ablation parameters at lower temperature, ramp, and time showed no increase in risk profile. The Subject Device with additional ablation parameters performs as intended and does not raise any new safety and/or efficacy concerns when compared to the legally marketed Predicate Device.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 882.4725 Radiofrequency lesion probe.
(a)
Identification. A radiofrequency lesion probe is a device connected to a radiofrequency (RF) lesion generator to deliver the RF energy to the site within the nervous system where a lesion is desired.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the seal of the Department of Health & Human Services. To the right of that is the FDA logo in blue, with the words "U.S. FOOD & DRUG" stacked on top of the word "ADMINISTRATION".
March 11, 2022
Relievant Medsystems, Inc. Thomas Slater VP, Quality and Regulatory Affairs 1230 Midas Way, Suite 200 Sunnyvale, California 94085
Re: K213836
Trade/Device Name: Intracept Intraosseous Nerve Ablation System Regulation Number: 21 CFR 882.4725 Regulation Name: Radiofrequency Lesion Probe Regulatory Class: Class II Product Code: GXI Dated: January 6, 2022 Received: January 23, 2022
Dear Thomas Slater:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part
1
801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Adam D. Pierce, Ph.D. Assistant Director DHT5A: Division of Neurosurgical, Neurointerventional and Neurodiagnostic Devices OHT5: Office of Neurological and Physical Medicine Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K213836
Device Name Intracept Intraosseous Nerve Ablation System
Indications for Use (Describe)
The Intracept Intraosseous Nerve Ablation System is intended to be used in conjunction with radiofrequency (RF) generators for the ablation of basivertebral nerves of the L3 through S1 vertebrae for the relief of chronic low back pain of at least six months duration that has not responded to at least six months of conservative care, and is also accompanied by features consistent with Type 1 or Type 2 Modic changes on an MRI such as inflammation, edema, vertebral endplate changes, disruption and fissuring of the endplate, vascularized fibrous tissues within the adjacent marrow, hypointensive signals (Type 1 Modic changes to the vertebral body marrow including replacement of normal bone marrow by fat, and hyperintensive signals (Type 2 Modic change).
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023 See PRA Statement below.
3
510(k) SUMMARY 5.
Applicant's Name and Address:
Relievant Medsystems, Inc. 1230 Midas Way, Suite 200 Sunnyvale, CA 94085
| Contact Person:
Telephone:
Facsimile: | Thomas A. Slater
650/368-1000 x135
650/298-9205 |
|---------------------------------------------|----------------------------------------------------------------|
| Date Prepared: | January 6, 2022 |
| Device Name: | |
| Device Generic Name: | RF Ablation Catheter and Accessories |
| Device Trade Name: | Intracept Intraosseous Nerve Ablation System |
| Device Classification: | II |
| Classification Name: | Radiofrequency lesion probe, 21 CFR 882.4725, Product Code GXI |
| Predicate Device: | |
Relievant Medsystems, Inc.: Intracept Intraosseous Nerve Ablation System (K190504)
Reference Devices:
Relievant Medsystems, Inc.: Intracept Intraosseous Nerve Ablation System:
Device Description:
The Intracept Intraosseous Nerve Ablation System) is comprised of sterile, singleuse components:
- The Intracept Access Instruments include introducers, cannulas and stylets that provide access ● to the intended site of radiofrequency (RF) ablation.
- The Intracept RF Probe conducts RF energy to the target location. ●
To obtain the energy needed for tissue ablation, the Intracept RF Probe is used with the Relievant Radiofrequency Generator (RFG).
The Intracept System uses RF ablation of the basivertebral nerve for relief of chronic low back pain and involves a two-step process. First, utilizing the Access Instruments, based on a minimally invasive, transpedicular or extrapedicular approach, a cannula and stylets are placed into the vertebral body to create a path or channel to the terminus of the basivertebral foramen. The RF Probe is then placed into this channel at the terminus of the basivertebral foramen and controlled RF energy is delivered to ablate the basivertebral nerve (BVN). This nerve has been identified as a proprioceptive sensory nerve with enervation of the vertebral endplates.
4
Indications for Use
The Intracept Intraosseous Nerve Ablation System is intended to be used in conjunction with radiofrequency (RF) generators for the ablation of basivertebral nerves of the L3 through S1 vertebrae for the relief of chronic low back pain of at least six months duration that has not responded to at least six months of conservative care, and is also accompanied by features consistent with Type 1 or Type 2 Modic changes on an MRI such as inflammation, edema, vertebral endplate changes, disruption and fissuring of the endplate, vascularized fibrous tissues within the adjacent marrow, hypointensive signals (Type 1 Modic change), and changes to the vertebral body marrow including replacement of normal bone marrow by fat, and hyperintensive signals (Type 2 Modic change).
Substantial Equivalence
Compared to the Predicate Device, there have been no changes to the patient population or the Indications for Use for the Intracept System. The Subject and Predicate Devices have a functionally equivalent design, with the difference being the introduction of an additional set of ablation parameters for ablation of the basivertebral nerve. The data provided herein demonstrates substantial equivalence to the Predicate Device.
5
| 510(k) Notification: Relievant Intracept® Intraosseous Nerve Ablation System (K213836) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| -- | ---------------------------------------------------------------------------------------- | -- | -- | -- | -- | -- | -- | -- | -- |
| Characteristic
Device Component | Relievant Medsystems
Subject:
Intracept System | Relievant Medsystems
Predicate:
Intracept System (K190504)
Reference Devices:
RF Probe (K180369)
Access Instruments (K170827) | Comparison |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Intended Use | To ablate the basivertebral nerves of the L3 to S1 vertebrae. | | Equivalent |
| Intracept System
Indication | The Intracept Intraosseous Nerve Ablation System is intended to
be used in conjunction with radiofrequency (RF) generators for the
ablation of basivertebral nerves of the L3 through S1 vertebrae for
the relief of chronic low back pain of at least six months duration
that has not responded to at least six months of conservative care,
and is also accompanied by features consistent with Type 1 or
Type 2 Modic changes on an MRI such as inflammation, edema,
vertebral endplate changes, disruption and fissuring of the
endplate, vascularized fibrous tissues within the adjacent marrow,
hypointensive signals (Type 1 Modic change), and changes to the
vertebral body marrow including replacement of normal bone
marrow by fat, and hyperintensive signals (Type 2 Modic change). | | Equivalent |
| Principle | Provide bipolar RF energy to the tissue between and around the
electrodes to achieve tissue ablation (i.e., cellular necrosis
through thermal ablation) | | Equivalent |
| Ablation Parameters:
Temperature | 85° C | 85° C | Equivalent |
| Ramp | 1°C/second
15 minutes (900 seconds) | 1°C/second
15 minutes (900 seconds) | Equivalent |
| Time | 75° C
0.5°C/second
7 minutes (420 seconds) | -- | Different |
| Access Instruments:
Design | No changes | | Equivalent |
| Materials | No changes | | Equivalent |
| Use | Single | | Equivalent |
| RF Probe:
Design | Removal of SensTx Chip | Optional SensTx Functionality | Different |
| Materials | No changes | No changes | Equivalent |
| Use | Single | Single | Equivalent |
Non-Clinical Performance Testing
Risk analysis of an additional set of ablation parameters at lower temperature, ramp, and time showed no increase in risk profile.
Conclusions
Based upon non-clinical performance testing, the Subject Device (Intracept System) with additional ablation parameters performs as intended and does not raise any new safety and/or efficacy concerns when compared to the legally marketed Predicate Device (Intracept System); therefore, these results support the substantial equivalence of the Subject and Predicate Device.